Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12941822 | 0.85 | LIPG (0.54) | LIPGHDAC1 | |
| SCHEMBL12597723 | 0.85 | LIPG (1.00) | LIPGPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL12941819 | 0.80 | LIPG (0.57) | LIPGHDAC1 | |
| SCHEMBL12941093 | 0.79 | LIPG (0.67) | LIPG | |
| SCHEMBL12597119 | 0.79 | LIPG (0.50) | LIPGHDAC1HDAC2 | |
| SCHEMBL12940717 | 0.77 | LIPG (0.45) | LIPGHDAC1HDAC2 | |
| SCHEMBL12941416 | 0.77 | LIPG (0.79) | LIPGPIK3CA | |
| SCHEMBL12597445 | 0.76 | LIPG (0.53) | LIPG | |
| SCHEMBL12941429 | 0.75 | LIPG (1.00) | LIPGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL12941451 | 0.73 | LIPG (0.68) | LIPGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2514749-B1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2015-02-25 | — | — | EP | disclosed |
| US-8754113-B2 | Oxadiazole derivative having endothelial lipase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-8754113-B2 | Oxadiazole derivative having endothelial lipase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| EP-2514749-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | Shionogi & Co., Ltd. (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| WO-2011074560-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | 塩野義製薬株式会社 (JP) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | LIPG, LPL, CEL | LIPG 1/4885HDAC1 615/4885HDAC2 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.